Atossa Therapeutics ATOS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Atossa Therapeutics (ATOS)
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.7376Market Cap
$92.79 MillionPrice-Earnings Ratio
-3.35Total Outstanding Shares
125.80 Million SharesTotal Employees
10Dividend
No dividendIPO Date
November 8, 2012SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
10202 5th avenue ne, Seattle, WA, 98125Homepage
https://www.atossatherapeutics.com
Historical Stock Splits
If you bought 180 shares of ATOS before August 26, 2016, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| April 20, 2018 | 1-for-12 (Reverse Split) |
| August 26, 2016 | 1-for-15 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-19.55 Million |
| Net Cash Flow From Investing Activities, Continuing | $-19,000 |
| Net Cash Flow From Operating Activities, Continuing | $-19.55 Million |
| Net Cash Flow | $-19.27 Million |
| Net Cash Flow From Financing Activities, Continuing | $304,000 |
| Net Cash Flow From Investing Activities | $-19,000 |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Operating Expenses | $29.49 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Revenues | $0 |
| Income/Loss From Continuing Operations After Tax | $-26.91 Million |
| Basic Earnings Per Share | $-0.22 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-26.91 Million |
| Comprehensive Income/Loss | $-26.91 Million |
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $5.80 Million |
| Current Assets | $77.11 Million |
| Other Current Assets | $76.16 Million |
| Liabilities | $5.80 Million |
| Noncurrent Liabilities | $0 |
| Wages | $1.06 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ATOS from trusted financial sources
â“’ 2025 Financhle. All Rights Reserved.